NF-κB, JNK, and TLR signaling pathways in hepatocarcinogenesis

Gastroenterology Research and Practice

Volumn , Issue , 2010, Pages

  Maeda, Shin ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CONCANAVALIN A; CYTOKINE; DIETHYLNITROSAMINE; GROWTH FACTOR; I KAPPA B; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MATRIX METALLOPROTEINASE; METHYLNITROSOUREA; MITOGENIC AGENT; MYELOID DIFFERENTIATION FACTOR 88; PARACETAMOL; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEPATITIS; ADAPTIVE IMMUNITY; ALCOHOL LIVER DISEASE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BONE MARROW CELL; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; FATTY LIVER; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LIVER; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER INJURY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROGNOSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR LOCALIZATION; VIRUS REPLICATION;

EID: 79251614052     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2010/367694     Document Type: Review

References (93)

1. F.X. Bosch, J. Ribes, M. Diaz, and R. Cléries, "Primary liver cancer: worldwide incidence and trends," Gastroenterology, vol. 127, pp. S5-S16, 2004.
2. K. Koike, T. Tsutsumi, H. Fujie, Y. Shintani, and K. Moriya, "Molecular mechanism of viral hepatocarcinogenesis," Oncology, vol. 62, no. 1, pp. 29-37, 2002.
3. N. Fausto, "Mouse liver tumorigenesis: models, mechanisms, and relevance to human disease," Seminars in Liver Disease, vol. 19, no. 3, pp. 243-252, 1999.
4. T. Sakurai, S. Maeda, L. Chang, and M. Karin, "Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 28, pp. 10544-10551, 2006.
5. N. Kato, H. Yoshida, S. Kioko Ono-Nita et al., "Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer," Hepatology, vol. 32, no. 2, pp. 405 -112, 2000.
6. S. H. Caldwell and D. M. Crespo, "The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease," Journal of Hepatology, vol. 40, no. 4, pp. 578-584, 2004.
7. E. E. Calle and R. Kaaks, "Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms," Nature Reviews Cancer, vol. 4, no. 8, pp. 579-591, 2004.
8. E. J. Park, J. H. Lee, G.-Y. Yu et al., "Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression," Cell, vol. 140, no. 2, pp. 197-208, 2010.
9. E. Dejardin, N. M. Droin, M. Delhase et al., "The lymphotoxin-jS receptor induces different patterns of gene expression via two NF-KB pathways," Immunity, vol. 17, no. 4, pp. 525-535, 2002.
10. S. Ghosh and M. Karin, "Missing pieces in the NF-κB puzzle," Cell, vol. 109, no. 2, pp. S81-S96, 2002.
11. F. Aslund and J. Beckwith, "The thioredoxin superfamily: redundancy, specificity, and gray-area genomics," Journal of Bacteriology, vol. 181, no. 5, pp. 1375-1379, 1999.
12. M. Karin, Y. Cao, F. R. Greten, and Z.-W. Li, "NF-κB in cancer: from innocent bystander to major culprit," Nature Reviews Cancer, vol. 2, no. 4, pp. 301-310, 2002.
13. N. Kabrun and P. J. Enrietto, "The Rel family of proteins in oncogenesis and differentiation," Seminars in Cancer Biology, vol. 5, no. 2, pp. 103-112, 1994.
14. D. Hanahan and R. A. Weinberg, "The hallmarks of cancer," Cell, vol. 100, no. 1, pp. 57-70, 2000.
15. P. W. Szlosarek and F. R. Balkwill, "Tumour necrosis factor α: a potential target for the therapy of solid tumours," The Lancet Oncology, vol. 4, no. 9, pp. 565-573, 2003.
16. D. C. Guttridge, C. Albanese, J. Y. Reuther, R. G. Pestell, and A. S. Baldwin Jr., "NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1," Molecular and Cellular Biology, vol. 19, no. 8, pp. 5785-5799, 1999.
17. K. S. Koch, S. Maeda, G. He, M. Karin, and H. L. Leffert, "Targeted deletion of hepatocyte Ikkβ confers growth advantages," Biochemical and Biophysical Research Communications, vol. 380, no. 2, pp. 349-354, 2009.
18. M. Karin and A. Lin, "NF-κB at the crossroads of life and death," Nature Immunology, vol. 3, no. 3, pp. 221-227, 2002.
19. S. Müerköster, A. ArIt, B. Sipos et al., "Increased expression of the E3-ubiquitin ligase receptor subunit/3TRCP1 relates to constitutive nuclear factor- KB activation and chemoresistance in pancreatic carcinoma cells," Cancer Research, vol. 65, no. 4, pp. 1316-1324, 2005.
20. Q. Cheng, H. H. Lee, Y. Li, T. P. Parks, and G. Cheng, "Upregulation of Bcl-x an BfI-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition," Oncogene, vol. 19, no. 42, pp. 4936-4940, 2000.
21. A. B. Kunnumakkara, S. Guha, S. Krishnan, P. Diagaradjane, J. Gelovani, and B. B. Aggarwal, "Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-KB-regulated gene products," Cancer Research, vol. 67, no. 8, pp. 3853-3861, 2007.
22. K. Sakamoto, S. Maeda, Y. Hikiba et al., "Constitutive NF-κB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth," Clinical Cancer Research, vol. 15, no. 7, pp. 2248-2258, 2009.
23. M. Egeblad and Z. Werb, "New functions for the matrix metalloproteinases in cancer progression," Nature Reviews Cancer, vol. 2, no. 3, pp. 161-174, 2002.
24. S. Maeda, Y. Hikiba, K. Sakamoto et al., "Ikappa B kinaseβ/nuclear factor-κB activation controls the development of liver metastasis by way of interleukin-6 expression," Hepatology, vol. 50, no. 6, pp. 1851-1860, 2009.
25. D.-I. Tai, S.-L. Tsai, Y-H. Chang et al., "Constitutive activation of nuclear factor κB in hepatocellular carcinoma," Cancer, vol. 89, no. 11, pp. 2274-2281, 2000.
26. R. Jiang, Y. Xia, J. Li et al., "High expression levels of IKKα and IKKβ are necessary for the malignant properties of liver cancer," International Journal of Cancer, vol. 126, no. 5, pp. 1263-1274, 2010.
27. Z.-W. Li, W. Chu, Y. Hu et al., "The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis," Journal of Experimental Medicine, vol. 189, no. 11, pp. 1839-1845, 1999.
28. S. Maeda, L. Chang, Z.-W. Li, J.-L. Luo, H. Leffert, and M. Karin, "IKKβ is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFα," Immunity, vol. 19, no. 5, pp. 725-737, 2003.
29. S. Maeda, H. Kamata, J.-L. Luo, H. Leffert, and M. Karin, "IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis," Cell, vol. 121, no. 7, pp. 977-990, 2005.
30. G. Tang, Y. Minemoto, B. Dibling et al., "Inhibition of JNK activation through NF-κB target genes," Nature, vol. 414, no. 6861, pp. 313-317, 2001.
31. N. Fausto, "Liver regeneration," Journal of Hepatology, vol. 32, no. 1, pp. 19-31, 2000.
32. W. E. Naugler, T. Sakurai, S. Kim et al., "Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production," Science, vol. 317, no. 5834, pp. 121-124, 2007.
33. G. He, G.-Y. Yu, V. Temkin et al., "Hepatocyte IKKβ/NFκB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation," Cancer Cell, vol. 17, no. 3, pp. 286-297, 2010.
34. T. Luedde, N. Beraza, V. Kotsikoris et al., "Deletion of NEMO/IKKγ in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma," Cancer Cell, vol. 11, no. 2, pp. 119-132, 2007.
35. T. Zhao, L. Yang, Q. Sun et al., "The NEMO adaptor bridges the nuclear factor-κB and interferon regulatory factor signaling pathways," Nature Immunology, vol. 8, no. 6, pp. 592-600, 2007.
36. Y. Hayakawa, S. Maeda, H. Nakagawa et al., "Effectiveness of IκB kinase inhibitors in murine colitis-associated tumorigenesis," Journal of Gastroenterology, vol. 44, no. 9, pp. 935-943, 2009.
37. M. Karin, Y. Yamamoto, and Q. M. Wang, "The IKK NFκB system: a treasure trove for drug development," Nature Reviews Drug Discovery, vol. 3, no. 1, pp. 17-26, 2004.
38. B. Dérijard, M. Hibi, L-H. Wu et al., "JNKl: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain," Cell, vol. 76, no. 6, pp. 1025-1037, 1994.
39. T. Kallunki, B. Su, I. Tsigelny et al., "JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation," Genes and Development, vol. 8, no. 24, pp. 2996-3007, 1994.
40. A. A. Mohit, J. H. Martin, and C. A. Miller, "p49(3F12) kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system," Neuron, vol. 14, no. 1, pp. 67-78, 1995.
41. X. Wang, A. Destrument, and C. Tournier, "Physiological roles of MKK4 and MKK7: insights from animal models," Biochimica et Biophysica Acta, vol. 1773, no. 8, pp. 1349-1357, 2007.
42. S. Gupta, T. Barrett, A. J. Whitmarsh et al., "Selective interaction of JNK protein kinase isoforms with transcription factors," The EMBO Journal, vol. 15, no. 11, pp. 2760-2770, 1996.
43. E. Shaulian and M. Karin, "AP-1 as a regulator of cell life and death," Nature Cell Biology, vol. 4, no. 5, pp. E131-E136, 2002.
44. C. R. Weston and R. J. Davis, "The JNK signal transduction pathway," Current Opinion in Genetics and Development, vol. 12, no. 1, pp. 14-21, 2002.
45. K. Sabapathy, Y. Hu, T. Kallunki et al., "JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development," Current Biology, vol. 9, no. 3, pp. 116-125, 1999.
46. K. Sabapathy and E. F. Wagner, "JNK2: a negative regulator of cellular proliferation," Cell Cycle, vol. 3, no. 12, pp. 1520-1523, 2004.
47. C.-Y. Kuan, D. D. Yang, D. R. Samanta Roy, R. J. Davis, P. Rakic, and R. A. Flavell, "The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development," Neuron, vol. 22, no. 4, pp. 667-676, 1999.
48. J. Hirosumi, G. Tuncman, L. Chang et al., "A central, role for JNK in obesity and insulin resistance," Nature, vol. 420, no. 6913, pp. 333-336, 2002.
49. C. Tournier, P. Hess, D. D. Yang et al., "Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway," Science, vol. 288, no. 5467, pp. 870-874, 2000.
50. N. Hanawa, M. Shinohara, B. Saberi, W A. Gaarde, D. Han, and N. Kaplowitz, "Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury," Journal of Biological Chemistry, vol. 283, no. 20, pp. 13565-13577, 2008.
51. H. Nakagawa, S. Maeda, Y. Hikiba et al., "Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation," Gastroenterology, vol. 135, no. 4, pp. 1311-1321, 2008.
52. M. Das, G. Sabio, F. Jiang, M. Rincón, R. A. Flavell, and R. J. Davis, "Induction of hepatitis by JNK-mediated expression of TNF-a," Cell, vol. 136, no. 2, pp. 249-260, 2009.
53. V. T. Samuel, Z.-X. Liu, X. Qu et al., "Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease," Journal of Biological Chemistry, vol. 279, no. 31, pp. 32345-32353, 2004.
54. Y. Kodama, T. Kisseleva, K. Iwaisako et al., "c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice," Gastroenterology, vol. 137, no. 4, pp. 1467-1477, 2009.
55. C. Tong, Z. Yin, Z. Song et al., "c-Jun NH2-terminal kinase 1 plays a critical role in intestinal homeostasis and tumor suppression," American Journal of Pathology, vol. 171, no. 1, pp. 297-303, 2007.
56. W Shibata, S. Maeda, Y. Hikiba et al., "c-Jun NH2-terminal kinase 1 is a critical regulator for the development of gastric cancer in mice," Cancer Research, vol. 68, no. 13, pp. 50315039, 2008.
57. A. Minden, A. Lin, M. McMahon et al., "Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK," Science, vol. 266, no. 5191, pp. 1719-1723, 1994.
58. G. J. Clark, J. K. Westwick, and C. J. Der, "pl20 GAP modulates Ras activation of jun kinases and transformation," Journal of Biological Chemistry, vol. 272, no. 3, pp. 1677-1681, 1997.
59. L. Hui, K. Zatloukal, H. Scheuch, E. Stepniak, and E. F. Wagner, "Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNKl-dependent p21 downregulation," Journal of Clinical Investigation, vol. 118, no. 12, pp. 3943-3953, 2008.
60. F. Bost, R. McKay, N. Dean, and D. Mercóla, "The JUN kinase/stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells," Journal of Biological Chemistry, vol. 272, no. 52, pp. 33422-33429,1997.
61. C. R. Weston, A. Wong, J. P. Hall, M. E. P. Goad, R. A. Flavell, and R. J. Davis, "The c-Jun NH2-terminal kinase is essential for epidermal growth factor expression during epidermal morphogenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 39, pp. 14114-14119, 2004.
62. M. Guma, J. Rius, K. X. Duong-Polk, G. G. Haddad, J. D. Lindsey, and M. Karin, "Genetic and pharmacological inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression," Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 21, pp. 8760-8765, 2009.
63. R. M. Strieter, P. J. Polverini, D. A. Arenberg et al., "Role of CX-C chemokines as regulators of angiogenesis in lung cancer," Journal of Leukocyte Biology, vol. 57, no. 5, pp. 752-762, 1995.
64. S. Yoshida, M. Ono, T. Shono et al., "Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alphadependent angiogenesis," Molecular and Cellular Biology, vol. 17, no. 7, pp. 4015-4023, 1997.
65. Q. Chang, Y. Zhang, K. J. Beezhold et al., "Sustained JNKl activation is associated with altered histone H3 methylations in human liver cancer," Journal of Hepatology, vol. 50, no. 2, pp. 323-333, 2009.
66. C. Tarn, S. Lee, Y. Hu, C. Ashendel, and O. M. Andrisani, "Hepatitis B virus X protein differentially activates RASRAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes," Journal of Biological Chemistry, vol. 276, no. 37, pp. 34671-34680, 2001.
67. M. Hibi, A. Lin, T. Smeal, A. Minden, and M. Karin, "Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain," Genes and Development, vol. 7, no. 11, pp. 2135-2148, 1993.
68. R. Eferl, R. Ricci, L. Kenner et al., "Liver tumor development: c-Jun antagonizes the proapoptotic activity of p53," Cell, vol. 112, no. 2, pp. 181-192, 2003.
69. P. Angel and M. Karin, "The role of Jun, Fos and the AP-I complex in cell-proliferation and transformation," Biochimica et Biophysica Acta, vol. 1072, no. 2-3, pp. 129-157, 1991.
70. A. Matsuzawa and H. Ichijo, "Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling," Biochimica et Biophysica Acta, vol. 1780, no. 11, pp. 1325-1336,2008.
71. F. Chen, K. Beezhold, and V. Castranova, "JNK1, a potential therapeutic target for hepatocellular carcinoma," Biochimica et Biophysica Acta, vol. 1796, no. 2, pp. 242-251, 2009.
72. H. Kamata, S.-I. Honda, S. Maeda, L. Chang, H. Hirata, and M. Karin, "Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases," Cell, vol. 120, no. 5, pp. 649-661, 2005.
73. M. Okuda, K. Li, M. R. Beard et al., "Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein," Gastroenterology, vol. 122, no. 2, pp. 366-375, 2002.
74. S. Inokuchi, T. Aoyama, K. Miura et al., "Disruption of TAKl in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 2, pp. 844849, 2010.
75. M. Takamura, Y. Matsuda, S. Yamagiwa et al., "An inhibitor of c-Jun NH2-terminal kinase, SP600125, protects mice from dgalactosamine/ lipopolysaccharide-induced hepatic failure by modulating BH3-only proteins," Life Sciences, vol. 80, no. 14, pp. 1335-1344, 2007.
76. O. Takeuchi and S. Akira, "Toll-like receptors; their physiological role and signal transduction system," International Immunopharmacology, vol. 1, no. 4, pp. 625-635, 2001.
77. L. A. J. O'Neill and A. G. Bowie, "The family of five: TIRdomain-containing adaptors in Toll-like receptor signalling," Nature Reviews Immunology, vol. 7, no. 5, pp. 353-364, 2007.
78. S. Akira, S. Uematsu, and O. Takeuchi, "Pathogen recognition and innate immunity," Cell, vol. 124, no. 4, pp. 783-801, 2006.
79. E. Seki and D. A. Brenner, "Toll-like receptors and adaptor molecules in liver disease: update," Hepatology, vol. 48, no. 1, pp. 322-335, 2008.
80. M. Isogawa, M. D. Robek, Y. Furuichi, and F. V. Chisari, "Tolllike receptor signaling inhibits hepatitis B virus replication in vivo," Journal of Virology, vol. 79, no. 11, pp. 7269-7272, 2005.
81. K. Visvanathan, N. A. Skinner, A. J. V Thompson et al., "Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein," Hepatology, vol. 45, no. 1, pp. 102-110, 2007.
82. A. Dolganiuc, S. Oak, K. Kodys et al., "Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation," Gastroenterology, vol. 127, no. 5, pp. 1513-1524, 2004.
83. K. Li, E. Foy, J. C. Ferreon et al., "Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 8, pp. 2992-2997, 2005.
84. I. Bjarnason, K. Ward, and T. J. Peters, "The leaky gut of alcoholism: possible route of entry for toxic compounds," The Lancet, vol. 1, no. 8370, pp. 179-182, 1984.
85. Y. Adachi, L. E. Moore, B. U. Bradford, W. Gao, and R. G. Thurman, "Antibiotics prevent liver injury in rats following long-term exposure to ethanol," Gastroenterology, vol. 108, no. 1, pp. 218-224, 1995.
86. T. Uesugi, M. Froh, G. E. Arteel, B. U. Bradford, and R. G. Thurman, "Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice," Hepatology, vol. 34, no. 1, pp. 101-108, 2001.
87. S. Q. Yang, H. Z. Lin, M. D. Lane, M. Clemens, and A. M. Diehl, "Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 6, pp. 2557-2562, 1997.
88. C. A. Rivera, P. Adegboyega, N. van Rooijen, A. Tagalicud, M. Allman, and M. Wallace, "Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of nonalcoholic steatohepatitis," Journal of Hepatology, vol. 47, no. 4, pp. 571-579, 2007.
89. R. F. Schwabe, E. Seki, and D. A. Brenner, "Toll-Like receptor signaling in the liver," Gastroenterology, vol. 130, no. 6, pp. 1886-1900, 2006.
90. T. Matsumura, T. Degawa, T. Takii et al., "TRAF6-NF-κB pathway is essential for interleukin-1 -induced TLR2 expression and its functional response to TLR2 ligand in murine hepatocytes," Immunology, vol. 109, no. 1, pp. 127-136, 2003.
91. S. Liu, D. J. Gallo, A. M. Green et al., "Role of toll-like receptors in changes in gene expression and NF-κB activation in mouse hepatocytes stimulated with lipopolysaccharide," Infection and Immunity, vol. 70, no. 7, pp. 3433-3442, 2002.
92. T. Matsumura, A. Ito, T. Takii, H. Hayashi, and K. Onozaki, "Endotoxin and cytokine regulation of toll-like receptor (TLR) 2 and TLR4 gene expression in murine liver and hepatocytes," Journal of Interferon and Cytokine Research, vol. 20, no. 10, pp. 915-921, 2000.
93. S. Maeda and M. Omata, "Inflammation and cancer: role of nuclear factor-kappaB activation," Cancer Science, vol. 99, no. 5, pp. 836-842, 2008.